03/23/2026 | Press release | Distributed by Public on 03/23/2026 11:23
MedPage Today highlighted research led by the University of Cincinnati's John Winhusen published in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue.
"These findings support weekly extended-release buprenorphine as another viable treatment option for pregnant and postpartum patients with opioid use disorder," Winhusen, PhD, principal investigator and lead author, director of the UC/UC Health Addiction Center, Donald C. Harrison endowed chair in medicine, vice chair of addiction sciences and professor in the Department of Psychiatry and Behavioral Neuroscience in UC's College of Medicine, told MedPage Today.
The research team additionally "did not see worse neonatal opioid withdrawal outcomes among infants exposed to extended-release buprenorphine, despite the higher overall buprenorphine exposure with the injectable formulation," Winhusen noted.
Read the MedPage Today article.
Featured photo at top of a pregnant woman. Photo/Stock Planet/iStock.
February 20, 2024
KFVS-TV in Cape Girardeau, Missouri highlighted a University of Cincinnati clinical trial testing a wearable neurostimulation device to help patients with opioid use disorder and post-traumatic stress disorder stick with medication treatment while finding the right dose.
April 12, 2023
The University of Cincinnati's Christine Wilder, MD, spoke with the Cincinnati Enquirer about Hamilton County data that overdose deaths in 2022 dropped for the first time in six years.
May 5, 2022
The University of Cincinnati's LaTrice Montgomery was a guest on the Cannabis Man podcast to discuss the current state of cannabis research.